Physician profile
Hitendrakumar M Patel
NPI 1407946486
$1,380.24
in general payments reported to CMS, 2019-2025
27 companies · $27.60 in 2025
The $27.60 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $488 · 2020: $331 · 2022: $16.54 · 2023: $362 · 2024: $155 · 2025: $27.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $545.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $261.52 | 2023 | Monarch Platform |
| Pfizer INC. | $147.83 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $97.54 | 2020-2024 | Farxiga |
| Abbvie INC. | $89.36 | 2023-2025 | |
| Amgen INC. | $87.63 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $77.07 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $74.23 | 2019-2022 | |
| Novo Nordisk INC | $60.35 | 2019-2024 | Wegovy |
| Glaxosmithkline, LLC. | $53.76 | 2019-2023 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $51.63 | 2020-2023 | Verquvo |
| Sanofi-Aventis U.S. LLC | $44.85 | 2019 | |
| Amarin Pharma, INC. | $41.68 | 2019-2020 | |
| Lilly USA, LLC | $33.25 | 2019-2024 | Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.05 | 2019 | |
| Vanda Pharmaceuticals INC. | $29.40 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $23.91 | 2020 | |
| Scpharmaceuticals INC. | $22.40 | 2024 | |
| Exact Sciences Corporation | $17.89 | 2024 | Cologuard Collection Kit |
| Dexcom, INC. | $17.71 | 2023 | Dexcom G6 Transmitter |
| Allergan, INC. | $17.47 | 2019 | |
| Phathom Pharmaceuticals, INC. | $16.68 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.24 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.96 | 2020 | |
| Nabriva Therapeutics, Plc | $14.06 | 2020 | |
| Mylan Specialty L.P. | $13.59 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.25 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hitendrakumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.